Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
